Nrx Pharmaceuticals Inc (NRXP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 1,443 | 4,595 | 20,054 | 27,605 | 1,859 |
| Receivables | N/A | N/A | N/A | N/A | 831 |
| TOTAL | $3,302 | $6,884 | $25,795 | $32,714 | $2,930 |
| Non-Current Assets | |||||
| Other Non-Current Assets | 349 | 431 | 21 | 15 | 11 |
| TOTAL | $349 | $431 | $21 | $15 | $11 |
| Total Assets | $3,651 | $7,315 | $25,816 | $32,729 | $2,941 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 320 | N/A | N/A | N/A | N/A |
| Accounts payable and accrued liabilities | 4,130 | 4,632 | 2,076 | 3,687 | 3,153 |
| Accrued Expenses | 10,528 | 5,238 | 5,769 | 2,844 | 42,762 |
| Other current liabilities | 5,639 | 17 | 37 | 4,874 | N/A |
| TOTAL | $21,863 | $19,048 | $15,585 | $11,923 | $46,164 |
| Non-Current Liabilities | |||||
| Long Term Debt | 5,011 | N/A | 2,822 | N/A | 548 |
| TOTAL | $5,011 | $N/A | $2,822 | $N/A | $548 |
| Total Liabilities | $26,874 | $19,048 | $18,407 | $11,923 | $46,712 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 16,916 | 9,570 | 7,156 | 6,664 | 269 |
| Common Shares | 15 | 8 | 67 | 59 | 43 |
| Retained earnings | -278,273 | -253,147 | -222,997 | -183,243 | -90,180 |
| TOTAL | $-23,223 | $-11,733 | $7,409 | $20,806 | $-43,771 |
| Total Liabilities And Equity | $3,651 | $7,315 | $25,816 | $32,729 | $2,941 |